Analyst Lance Wilkes from Bernstein maintained a Hold rating on HCA Healthcare and increased the price target to $417.00 from $404.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lance Wilkes has given his Hold rating due to a combination of factors that balance both positive and negative aspects of HCA Healthcare’s current performance. The company has demonstrated strong operating margins, which have exceeded expectations, reflecting effective management strategies. However, this positive margin performance is tempered by a noticeable slowdown in volume growth, which aligns with the anticipated normalization following the COVID-19 pandemic disruptions.
Despite raising the price target to $417, Wilkes maintains a Market-Perform rating as the risks associated with margin pressures and policy impacts on bad debts remain concerns. Additionally, the company’s guidance for slower volume growth further supports the Hold rating, as it suggests potential challenges in sustaining high growth rates. These elements combined lead to a balanced outlook, justifying the Hold recommendation.
In another report released on August 14, Robert W. Baird also maintained a Hold rating on the stock with a $423.00 price target.